8-KOther EventsExhibits & Filings

Zoetis Inc. 8-K Report, Corporate Update (Jul 6, 2018)

Filed July 6, 2018For Securities:ZTS

Summary

Zoetis Inc. (ZTS) announced via an 8-K filing on July 6, 2018, that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired in connection with its previously announced acquisition of Abaxis, Inc. This development signifies a significant step forward in the regulatory approval process for the acquisition. Investors should view this as positive news, indicating that a key antitrust hurdle has been cleared. While the transaction still requires Abaxis shareholder approval and the satisfaction of other customary closing conditions, the expiration of the HSR waiting period reduces a notable uncertainty and moves Zoetis closer to integrating Abaxis's complementary portfolio and expanding its presence in the diagnostics market.

Key Highlights

  • 1Expiration of Hart-Scott-Rodino (HSR) waiting period for Zoetis's acquisition of Abaxis.
  • 2This is a crucial antitrust clearance for the proposed transaction.
  • 3The joint press release with Abaxis confirms the expiration.
  • 4The acquisition is moving forward, pending Abaxis shareholder approval and other closing conditions.
  • 5The filing includes cautionary statements regarding forward-looking information and potential risks associated with the transaction and integration.
  • 6Information is provided on how investors can access further details, including Abaxis's proxy statement, for the transaction.

Frequently Asked Questions

The main news is that Zoetis has received antitrust clearance for its acquisition of Abaxis, as indicated by the expiration of the Hart-Scott-Rodino waiting period.

No, the acquisition is not yet complete. While antitrust approval has been granted, the transaction is still subject to Abaxis shareholder approval and other customary closing conditions.

The filing highlights risks such as the possibility of termination of the merger agreement, legal proceedings, failure to obtain necessary approvals, failure to realize anticipated benefits, integration challenges, and potential negative impacts on business relationships.

Investors can find more information by reviewing Abaxis's definitive proxy statement, which is available on the SEC's website. Additional details about both companies' filings can also be found on the SEC's website or by contacting Abaxis directly.